DWA
EVLO

Dorsey Wright & Associates’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Dorsey Wright & Associates’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-160
Closed -$44K – 359
2021
Q2 		$44K Hold
160
– – 0.01% 228
2021
Q1 		$34.3K Buy
+160
New +$44.2K 0.4% 135

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dorsey Wright & Associates's EVLO Position: Q3 2021 in Review

Dorsey Wright & Associates sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2021, closing a stake of 160 shares — an estimated $44K sold.

Dorsey Wright & Associates first reported a position in EVLO in Q1 2021 and held it in 2 quarters. The position peaked at $44K in Q2 2021. 64 funds tracked by Wall St. Rank hold EVLO as of Q3 2021.

  • Dorsey Wright & Associates reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 160 Evelo Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $44K.
  • Dorsey Wright & Associates first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Dorsey Wright & Associates's Evelo Biosciences, Inc. Common Stock position peaked at $44K in Q2 2021.
  • 64 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2021.

Based on Dorsey Wright & Associates's 13F filing for Q3 2021, filed 26 Oct 2021.